McKesson Corporation (MCK) FY2025 10-K Annual Report
McKesson Corporation (MCK) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on May 9, 2025. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
McKesson Corporation FY2025 10-K Analysis
Business Overview
- • Core business model centered on government contracts requiring compliance with procurement laws and regulations
- • Emphasis on risks related to funding availability, contract renewal uncertainty, and heightened liability under government agreements
Management Discussion & Analysis
- • Revenue $310.5B, up 4.2% YoY from $297.9B driven by pharmaceutical distribution growth
- • Operating margin 2.3% vs 2.1% in prior year, reflecting improved supply chain efficiencies
Risk Factors
- • Opioid-related litigation liability $6.4 billion accrued as of March 31, 2025 with uncertainty on ultimate losses or resolution timing
- • Geopolitical exposure to U.S. healthcare market via largest customer CVS Health accounting for 24% of revenue and 23% of receivables
McKesson Corporation FY2025 Key Financial MetricsXBRL
Revenue
$359.1B
▲ +16.2% YoY
Net Income
$3.3B
▲ +9.8% YoY
Gross Margin
3.7%
▼ -44bp YoY
Operating Margin
1.2%
▼ -3bp YoY
Net Margin
0.9%
▼ -5bp YoY
ROE
-158.9%
▼ -656bp YoY
Total Assets
$75.1B
▲ +11.4% YoY
EPS (Diluted)
$25.72
▲ +14.9% YoY
Operating Cash Flow
$6.1B
▲ +41.1% YoY
Source: XBRL data from McKesson Corporation FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on McKesson Corporation
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.